Compounds of formula (1a) and pharmaceutically acceptable salts, solvates, and hydrates thereof and related methods of modulatin perforin activity on a cell: wherein Ring A is selected from a 6-10 membered aryl, 5-6 membered cycloalkyi, 5-6 membered heteroaryl or 5-6 membered heterocyclyl, wherein the heteroaryl and heterocyclyl rings comprise at least one heteroatom selected from N, O or S; and wherein the aryl, cycloalkyi, heteroaryl or heterocyclyl rings are optionally substituted with 1 to 3 substituents selected from halo, nitro, —C
1
-Cealkyl, —C
1
-Ceaminoalkyl, —C
1
-C
6
hydroxyalkyl, -haloC
1
-C
6
alkyl, —C
1
-C
6
alkoxyl, -haloC
1
—C
公式(1a)的化合物及其药学上可接受的盐、溶剂化物和水合物,以及相关的调节细胞穿孔素活性的方法:其中环A选自6-10成员芳基、5-6成员环烷基、5-6成员杂芳基或5-6成员杂环烷基,其中杂芳基和杂环烷基环中至少包含一个选自N、O或S的杂原子;环A、环烷基、杂芳基或杂环烷基环可以选择地被1到3个取代基所取代,所述取代基选自卤素、硝基、-C1-Ce烷基、-C1-Ce氨基烷基、-C1-C6羟基烷基、-卤基C1-C6烷基、-C1-C6烷氧基、-卤基C1-C
US9896443B2
申请人:——
公开号:US9896443B2
公开(公告)日:2018-02-20
Substituted arylsulphonamides as inhibitors of perforin-mediated lysis
作者:Julie A. Spicer、Christian K. Miller、Patrick D. O'Connor、Jiney Jose、Kristiina M. Huttunen、Jagdish K. Jaiswal、William A. Denny、Hedieh Akhlaghi、Kylie A. Browne、Joseph A. Trapani
DOI:10.1016/j.ejmech.2017.05.048
日期:2017.9
The structure-activity relationships for a series of arylsulphonamide-based inhibitors of the pore forming protein perforin have been explored. Perforin is a key component of the human immune response, however inappropriate activity has also been implicated in certain auto-immune and therapy induced conditions such as allograft rejection and graft versus host disease. Since perforin is expressed exclusively by cells of the immune system, inhibition of this protein would be a highly selective strategy for the immunosuppressive treatment of these disorders. Compounds from this series were demonstrated to be potent inhibitors of the lytic action of both isolated recombinant perforin and perforin secreted by natural killer cells in vitro. Several potent and soluble examples were assessed for in vivo pharmacokinetic properties and found to be suitable for progression to an in vivo model of transplant rejection. (C) 2017 The Authors. Published by Elsevier Masson SAS.
查看更多